Dyax Corp.
Description Dyax Corp., a biopharmaceutical company, engages in the identification, development, and commercialization of treatments for plasma kallikrein-mediated (PKM) angioedemas. It offers KALBITOR for the treatment of acute attacks of hereditary angioedema (HAE). It is also involved in the preclinical development of DX-2930, a potent and specific fully human monoclonal antibody that is an inhibitor of plasma kallikrein, which would be a candidate to prophylactically treat PKM angioedema. The company distributes KALBITOR through a network of wholesale and specialty pharmacy arrangements. It has strategic partnerships with CVie Therapeutics for the development and commercialization of KALBITOR in the treatment of HAE and other angioedema indications in China; and Novellus Biopharma AG for the development and commercialization of KALBITOR for the treatment of HAE and other angioedema indications in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico, and Venezuela. The company also has an agreement with CMIC Co., Ltd. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other angioedema indications in Japan; and a collaboration agreement with Sigma-Tau Rare Diseases S.A. to develop and commercialize subcutaneous ecallantide for the treatment of HAE and other therapeutic indications in Europe, Russia, Australia, and New Zealand. Dyax Corp. was founded in 1989 and is headquartered in Burlington, Massachusetts. To view the detailed information, you need to SUBSCRIBE with us. |
 |